-
-
-
-
-
-
-
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
-
-
-
-
-
-
-
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) approves $750M share repurchase program
-
-
-
-
-
-
-
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces CFO Transition
-
-
-
-
-
-
-
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology
-
-
-
-
77,774 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All